Reviewing Dynavax Technologies Corporation (DVAX) & Its Competitors

Dynavax Technologies Corporation (NASDAQ: DVAX) is one of 292 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Dynavax Technologies Corporation to related companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, risk and profitability.

Insider and Institutional Ownership

60.2% of Dynavax Technologies Corporation shares are owned by institutional investors. Comparatively, 50.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 2.9% of Dynavax Technologies Corporation shares are owned by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Dynavax Technologies Corporation has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Dynavax Technologies Corporation’s peers have a beta of 6.66, meaning that their average share price is 566% more volatile than the S&P 500.

Profitability

This table compares Dynavax Technologies Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dynavax Technologies Corporation -1,323.99% -92.09% -78.45%
Dynavax Technologies Corporation Competitors -5,527.68% -454.18% -42.49%

Earnings and Valuation

This table compares Dynavax Technologies Corporation and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Dynavax Technologies Corporation $7.71 million -$94.16 million -9.09
Dynavax Technologies Corporation Competitors $258.58 million $65.85 million -7.43

Dynavax Technologies Corporation’s peers have higher revenue and earnings than Dynavax Technologies Corporation. Dynavax Technologies Corporation is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and recommmendations for Dynavax Technologies Corporation and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dynavax Technologies Corporation 0 0 5 0 3.00
Dynavax Technologies Corporation Competitors 739 2973 11061 223 2.72

Dynavax Technologies Corporation presently has a consensus price target of $27.80, suggesting a potential upside of 23.83%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 30.72%. Given Dynavax Technologies Corporation’s peers higher possible upside, analysts clearly believe Dynavax Technologies Corporation has less favorable growth aspects than its peers.

Summary

Dynavax Technologies Corporation peers beat Dynavax Technologies Corporation on 7 of the 12 factors compared.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.